Valuation
- Market cap
- 130,881,000
- Revenue TTM
- $4,900,000
- Net income TTM
- $-173,800,000
- PE ratio
- 0.00
- Forward PE
- 6.62
- Profit margin
- -3,546.94%
- Debt to equity
- -1.23
Trading
- Volume
- 56,600
- Avg volume
- 212,528
- Day's range
- $3.51 – $3.68
- Shares out
- 37,182,000
- Stochastic %K
- 37%
- Beta
- 1.40
- Analysts
- Strong Sell
- Price target
- $17.50
Company profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . Th...
Show more
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 310 665 2928
- Website
- https://www.armatapharma.com
- Address
- 5005 McConnell Avenue, Los Angeles, United States
Latest news
No headlines yet.
